Myocilin Mutations Are Not a Major Cause of Primary Congenital Glaucoma in Iranian Patients

Elahe Elahi, PhD1,2,3; Mehrnaz Narooie-Nejhad, MS4; Fatemeh Suri, MS1; Shahin Yazdani, MD5

1School of Biology, College of Science, University of Tehran, Tehran, Iran
2Department of Biotechnology, College of Science, University of Tehran, Tehran, Iran
3Center of Excellence in Biomathematics, Statistics and Computer Science, University of Tehran, Tehran, Iran
4National Institute of Genetic Engineering and Biotechnology, Tehran, Iran
5Ophthalmic Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran

*The study was funded by the Research Division of the College of Science, University of Tehran, Tehran, Iran

Purpose: To assess the frequency of mutations in the Myocilin (MYOC) gene in Iranian patients affected with primary congenital glaucoma (PCG).

Methods: The individuals evaluated herein are among a larger cohort of 100 patients who had previously been screened for CYP1B1 mutations. Eighty subjects carried mutations in CYP1B1, but the remaining 20 patients who did not, underwent screening for MYOC mutations for the purpose of the study. MYOC exons in the DNA were polymerase chain reaction (PCR) amplified and sequenced. Sequencing was performed using PCR primers, the ABI big dye chemistry and an ABI3730XL instrument. Sequences were analyzed by comparing them to reference MYOC sequences using the Sequencher software.

Results: Four MYOC sequence variations were observed among the patients, but none of them were considered to be associated with disease status. Three of these variations were single nucleotide polymorphisms already reported not to be disease causing, the fourth variation created a synonymous codon and did not affect any amino acid change.

Conclusion: In this cohort, MYOC mutations were not observed in any Iranian subject with PCG. It is possible that in a larger sample, a few subjects carrying disease causing MYOC mutations could have been observed. But our results show that the contribution of MYOC to PCG status in Iran is small if any.

Keywords: Primary Congenital Glaucoma; Myocilin

INTRODUCTION

Glaucoma affects more than 60 million people worldwide and is the second leading cause of blindness.1 It has traditionally been categorized based on etiology, anatomy of the anterior chamber angle, and age of onset.2 Two of the major forms of the disease are primary open angle glaucoma (POAG; OMIM 137760) and primary congenital glaucoma (PCG; OMIM 231300). PCG is a severe form of glaucoma that manifests at birth or early childhood and is associated with developmental defects in the trabecular meshwork.3 POAG is the most
common form of glaucoma in Western countries and usually affects individuals past the age of 40 years. Genetic analysis has identified more than ten loci linked to POAG, attesting to its high genetic heterogeneity. Genes at three of these loci have been identified: Myocilin (MYOC at GLC1A; OMIM 601652), Optineurin (OPTN at GLC1E; OMIM 602432), and WD repeat containing protein 36 (WDR36 at GLC1G; OMIM 609669). Mutations in MYOC have been observed more frequently than mutations in OPTN and WDR36. Three loci have been found for PCG, and genes at two of these loci have been identified: the Cytochrome P4501B1 gene (CYP1B1 at GLC3A; OMIM 601771) and the Latent Transforming Growth Factor (TGF) Beta Binding Protein 2 gene (LTBP2 at GLC3C; OMIM 602091). CYP1B1 mutations are most common, and have been observed in approximately 70% of Iranian PCG patients. Although CYP1B1 is generally associated with PCG, several studies have reported CYP1B1 mutations in POAG patients and it is now apparent that this gene can also cause POAG, particularly the juvenile onset form of the disease (juvenile open angle glaucoma, JOAG). Less often, MYOC mutations have been observed in PCG patients. MYOC mutations were sometimes observed in conjunction with CYP1B1 mutations and sometimes without CYP1B1 mutations. The biological significance of these observations is that some cases of PCG and POAG may share a common etiology. Herein, we report data on the frequency of MYOC mutation among Iranian PCG patients.

METHODS

This study was performed in accordance with the Declaration of Helsinki and with approval by the Ethics Board of the National Institute of Genetic Engineering and Biotechnology in Iran, and the University of Tehran. Informed consent was obtained from all patients or their guardians. Originally, 123 unrelated Iranian PCG patients were recruited for genetic studies. Slitlamp biomicroscopy, intraocular pressure (IOP) measurement, gonioscopic evaluation of the angle, fundus examination, and perimetry had been performed whenever possible. PCG manifested by IOP ≥ 21 (range, 21-56) mmHg in at least one eye before treatment, corneal edema and/or opacification, Descemet’s membrane rupture, megalocornea (corneal diameter exceeding 12 mm), and optic nerve head changes suggestive of glaucoma including high cup/disc ratio or neural rim thinning or notching. The cup/disc ratio of affected eyes ranged from 0.3 to total (average value, 0.58). Mutation screening for CYP1B1 was performed by direct sequencing and 80 patients among the initial 123 cases, were shown to have mutations in this gene. Twenty of the remaining 43 patients were available for further study. DNA was extracted from these 20 patients and the three MYOC exons were amplified by polymerase chain reaction (PCR) and subsequently screened for mutations by direct sequencing. Sequencing was performed using PCR primers and the ABI big dye chemistry and an ABI3730XL instrument (Applied Biosystems, Foster City, USA). Sequences were analyzed by comparing them to reference MYOC sequences (NT_004487, NM_000261, and NP_000252) using the Sequencher software (Gene Codes Corp., Ann Arbor, USA). PCR conditions and MYOC primer sequences are available upon request. For assessing the frequency of MYOC mutations, data on the 80 patients with CYP1B1 mutations and the 20 patients without CYP1B1 mutations in whom MYOC was sequenced were considered. The 23 patients without CYP1B1 mutations who were not available for MYOC screening were not included in the analysis.

RESULTS

Overall 20 patients including ten male and 10 female subjects, all with age of onset of PCG less than 3 years, were studied. Sequencing MYOC exons revealed four sequence variations. Three of these: c.-83G>A, c.227G>A and IVS2+35G>A, were observed in heterozygous state each in 6 distinct individuals and in homozygous state in 1, 1 and 6 individuals respectively. All of these are single nucleotide polymorphisms (SNPs) that have already been reported not to be disease causing. The same variations have
previously been observed as high frequency polymorphisms in Iranian JOAG patients. The fourth variation, c.1041T>A, resulting in Y347Y, is also very unlikely to be associated with disease status because it creates a synonymous codon and does not cause any amino acid change; it was observed in the heterozygous state in one subject.

DISCUSSION
We have ascertained that MYOC is not a major cause of PCG among Iranian patients. Although this gene was sequenced in only 20 patients and disease causing mutations were not found, these 20 patients are among 100 subjects whose status regarding CYP1B1 is already known. Of the 100 patients, 80 have been shown to harbor disease causing CYP1B1 mutations and are unlikely to simultaneously carry MYOC mutations. Therefore, it can reasonably be surmised that mutations in MYOC mutations were not the cause of PCG in 100 recruited patients. Studies comparable to ours have been reported on PCG patients from India and China. In studies from India, four among approximately 150 patients (MYOC screened in 72; the remaining carried CYP1B1 mutations) in one study, and five among 200 subjects in another report carried MYOC mutations. In a study from China, three patients among 116 subjects harbored MYOC mutations. It is possible that in a larger cohort of Iranian PCG patients, a few individuals carrying MYOC mutations would have been identified. But clearly, the results of this study show that the contribution of MYOC to PCG status in Iran is small if any. Notably the contribution of CYP1B1, which is usually associated with PCG, to JOAG has been shown to be very significant in Iran. In fact, MYOC and CYP1B1 may contribute equally to JOAG status among Iranian patients. The explanation for this may be that some cases of JOAG may be late onset forms of PCG rather than early onset forms of POAG. Fewer cases of PCG may share a common etiology with classic open angle glaucoma.

Since MYOC and CYP1B1 mutations have been observed in the same individual in a few cases, a digenic mode of pathogenesis for glaucoma has sometimes been proposed. To the best of our knowledge, the CYP1B1 mutation in such patients has always been R368H. The proposed digenic mode of pathogenesis for PCG should be considered with caution because it is not absolutely clear that the R368H mutation in CYP1B1 actually is a disease associated variation. Its frequency in PCG affected and control groups in India has been reported to be similar. We have recently made the same observation among Iranian PCG patients and control individuals (unpublished data). We have also noted that the variation found in PCG patients harboring only one mutated CYP1B1 allele is frequently R368H, suggesting that it may be a neutral polymorphism. Notably, both observations of a MYOC mutation coexisting with a R368H CYP1B1 allele were made in patients from India. These observations emphasize that it is unclear whether MYOC and CYP1B1 work in a common pathway toward PCG. The manner in which mutations in MYOC may affect PCG status remains unknown.

Acknowledgements
We thank the patients and their guardians for consenting to participate in this study. We also acknowledge the Iranian National Science Foundation and the Ophthalmic Research Center at Shahid Beheshti University of Medical Sciences for funding this research.

REFERENCES
1. Wiggs JL. Genetic etiologies of glaucoma. Arch Ophthalmol 2007;125:30-37.
2. Sarfarazi M. Recent advances in molecular genetics of glaucomas. Hum Mol Genet 1997;6:1667-1677.
3. Ho CL, Walton DS. Primary Congenital Glaucoma: 2004 Update. J Pediatr Ophthalmol Strabismus 2004;41:271-281.
4. Fan BJ, Wang DY, Lam DS, Pang CP. Gene mapping for primary open angle glaucoma. Clin Biochem 2006;39:249-258.
5. Stone EM, Fingert JH, Alward WL, Nguyen TD,
Polansky JR, Sunden SL, et al. Identification of a gene that causes primary open angle glaucoma. *Science* 1997;275:668-670.

6. Rezaie T, Child A, Hitchings R, Brice G, Miller L, Coca-Prados M, et al. Adult-onset primary open angle glaucoma caused by mutations in optineurin. *Science* 2002;295:1077-1079.

7. Monemi S, Spaeth G, DaSilva A, Popinchalk S, Ilitch E, Liebmann J, et al. Identification of a novel adult-onset primary open-angle glaucoma (POAG) gene on 5q22.1. *Hum Mol Genet* 2005;14:725-733.

8. Stoilov I, Akarsu AN, Sarfarazi M. Identification of three different truncating mutations in cytochrome P4501B1 (CYP1B1) as a principle cause of primary congenital glaucoma (Buphthalmos) in families linked to the GLC3A locus on Chromosome 2p21. *Hum Mol Genet* 1997;6:641-647.

9. Ali M, McKibbin M, Booth A, Parry DA, Jain P, Riazuddin SA, et al. Null mutations in LTBP2 cause primary congenital glaucoma. *Am J Hum Genet* 2009;84:664-671.

10. Chitsazian F, Tusi BK, Elahi E, Saroei HA, Sanati MH, Yazdani S, et al. CYP1B1 mutation profile of Iranian primary congenital glaucoma patients and associated haplotypes. *J Mol Diagn* 2007;9:382-393.

11. Kumar A, Basavaraj MG, Gupta SK, Qamar I, Ali AM, Bajaj V, et al. Role of CYP1B1, MYOC, OPTN and OPTC genes in adult-onset primary open-angle glaucoma: predominance of CYP1B1 mutations in Indian patients. *Mol Vis* 2007;13:667-676.

12. López-Garrido MP, Sánchez-Sánchez F, López-Martínez F, Aroca-Aguilar JD, Blanco-Marchite C, Coca-Prados M, et al. Heterozygous CYP1B1 gene mutations in Spanish patients with primary open-angle glaucoma. *Mol Vis* 2006;12:748-755.

13. Melki R, Colomb E, Lefort N, Brézin AP, Garchon HJ. CYP1B1 mutations in French patients with early-onset primary open-angle glaucoma. *J Med Genet* 2004;41:647-651.

14. Bayat B, Yazdani S, Alavi A, Chiani M, Chitsazian F, Tusi BK, et al. Contributions of MYOC and CYP1B1 mutations to JOAG. *Mol Vis* 2008;14:508-517.

15. Kaur K, Reddy AB, Mukhopadhyay A, Mandal AK, Hasnain SE, Ray K, et al. Myocilin gene implicated in primary congenital glaucoma. *Clin Genet* 2005;67:335-340.

16. Chakrabarti S, Kaur K, Komatireddy S, Acharya M, Devi KR, Mukhopadhyay A, et al. Gln48His is the prevalent myocilin mutation in primary open angle and primary congenital glaucoma phenotypes in India. *Mol Vis* 2005;11:111-113.

17. Chen Y, Jiang D, Yu L, Katz B, Zhang K, Wan B, et al. CYP1B1 and MYOC mutations in 116 Chinese patients with primary congenital glaucoma. *Arch Ophthalmol* 2008;126:1443-1447.

18. Vincent AL, Billingsley G, Buys Y, Levin AV, Priston M, Trope G, et al. Digenic inheritance of early-onset glaucoma: CYP1B1, a potential modifier gene. *Am J Hum Genet* 2002;70:448-460.

19. Narooie-Nejad M, Paylakhi SH, Shojaee SM, Fazlali Z, Rezaei Kanavi M, Nilforushan N, et al. Loss of function mutations in the gene encoding latent transforming growth factor beta binding protein 2, LTBP2, cause primary congenital glaucoma. *Hum Mol Genet* 2009;18:3969-3977.

20. Acharya M, Mukhopadhyay A, Bhattacharjee A, Thakur SK, Bandyopadhyay AK, Ray K, et al. Complex genetics of glaucoma: defects in CYP1B1, and not MYOC, cause pathogenesis in an early-onset POAG patient with double variants at both loci. *J Genetics* 2008;87:265-269.

21. Alward WL, Fingert JH, Coote MA, Johnson AT, Lerner SF, Junqua D, et al. Clinical features associated with mutations in the chromosome 1 open-angle glaucoma gene (GLC1A). *N Engl J Med* 1998;338:1022-1027.

22. Pang CP, Leung YF, Fan B, Baum L, Tong WC, Lee WS, et al. TIGR/MYOC gene sequence alterations in individuals with and without primary open-angle glaucoma. *Invest Ophthalmol Vis Sci* 2002;43:3231-3235.

23. Suri F, Kalhor R, Zargar SJ, Niforosohan N, Yazdani S, Nezari H, et al. Screening of common CYP1B1 mutations in Iranian POAG patients using a microarray-based PrASE protocol. *Mol Vis* 2008;14:2349-2356.